Indication

ABCC6 Deficiency

1 clinical trial

1 product

Clinical trial

A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period in Adults With ABCC6 Deficiency Manifesting as Pseudoxanthoma Elasticum (PXE)

Status: Active (not recruiting), Estimated PCD: 2023-11-07

Product